Close Menu

NEW YORK ­– Quest Diagnostics and the US Food and Drug Administration announced on Saturday that the company received Emergency Use Authorization from the FDA to for the use of Quest's SARS-CoV-2 RNA test for pool sampling to detect the coronavirus.

The agency reissued an EUA to the Secaucus, New Jersey-based company for the test, which is the first to receive the designation for pooled sampling for COVID-19 testing.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.